Phase 3 Stroke Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older.
• People who have had an acute ischemic stroke (a stroke caused by a blocked blood vessel) and were treated with a clot-dissolving medication (alteplase or tenecteplase) given through a drip within 4.5 hours of their stroke starting, and who could receive the study drug within 3 hours of starting that clot-dissolving treatment.
• People who still have a meaningful level of stroke-related disability (a score above 5 on a standard stroke severity scale) when assessed 1 hour after starting the clot-dissolving treatment, and before being enrolled in the trial.
• People for whom written consent has been provided, either by the patient themselves or by an authorised representative.

Who may not be able to join:

• People whose stroke was confirmed by imaging (such as a CT or MRI scan of blood vessels) to be caused by a blockage in one of several specific large brain arteries, or who are already planned to have a procedure to remove or treat the blockage (such as mechanical clot removal or an artery-opening procedure).
• People whose imaging after clot-dissolving treatment shows bleeding inside the brain.
• People whose stroke is confirmed or suspected to have been caused by a blood clot travelling from the heart.
• People whose stroke has a known cause other than a narrowed artery, such as certain blood vessel diseases (including moyamoya disease, artery tearing, or artery inflammation), blood-clotting disorders, or blood diseases.
• People who took antiplatelet medications (such as aspirin or clopidogrel) within one week before their stroke, took newer blood-thinning medications within 48 hours before their stroke, or were taking warfarin with a blood-thinning level that was too high (INR above 1.7).
• People who have previously had a moderate or severe stroke that left lasting neurological effects.
• People who had any significant level of disability before this stroke (a pre-stroke disability score above 1 on a standard scale).
• People who have a severe reduction in consciousness at the time of assessment (a score of 2 or more on the consciousness item of a standard stroke scale).
• People whose post-treatment brain imaging shows that the area of brain damage covers more than half of the region supplied by the affected artery.
• People who have a known reason why antiplatelet medications would not be safe for them, such as a bleeding disorder or active bleeding elsewhere in the body.
• People with a known allergy to aspirin.
• People who are expected to need blood-thinning (anticoagulant) medication during the study period, for example due to an irregular heart rhythm (atrial fibrillation), a mechanical heart valve, blood clots in the legs or lungs, or certain clotting conditions.
• People with cancer, those on regular kidney dialysis, those with severely reduced kidney function (based on specific blood test results), those with significantly reduced liver function (based on specific liver blood test results), or those with severe heart failure.
• People with a serious non-heart-related illness where survival of less than 6 months is expected.
• People who would not be available for follow-up appointments during the study.
• People with dementia, a psychiatric condition, or another known neurological condition that would make follow-up difficult.
• People who are currently taking part in another clinical treatment study that is still ongoing.
• People who the trial investigators consider unsuitable for the study for any other reason (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.